Plasma and aqueous humor angiotensin-converting enzyme levels in patients with diabetic retinopathy

Current Eye Research

Volumn 35, Issue 3, 2010, Pages 230-234

  Aydin, Erdinc ^a   Demir, Helin Deniz ^a   Sahin, Semsettin ^a  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

Author keywords

Angiotensin converting enzyme; Aqueous humor; Diabetes mellitus; Diabetic retinopathy; Plasma; Retinal angiogenesis

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ANGIOGENESIS; AQUEOUS HUMOR; ARTICLE; CATARACT; CATARACT EXTRACTION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE COURSE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; NONPROLIFERATIVE DIABETIC RETINOPATHY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETINA BLOOD VESSEL;

AGED; AQUEOUS HUMOR; CHEMILUMINESCENT MEASUREMENTS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A;

EID: 77950816872     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713680903484242     Document Type: Article

References (31)

1. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGFreceptor chimeric proteins. Proc Natl Acad Sci USA 1995;92: 10457-10461.
2. Dzau VJ, Ingelfinger JR, Pratt RE. Regulation of tissue renin and angiotensin gene expressions. J Cardiovasc Pharmacol 1986;8:S11-S16.
3. Paul M, Wagner J, Dzau VJ. Gene expression of the reninangiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J Clin Invest 1993;91: 2058-2064. (Pubitemid 23141478)
4. Gilbert RE, Krum H, Wilkinson-Berka J, et al. The reninangiotensin system and the long-term complications of diabetes: Pathophysiological and therapeutic considerations. Diabet Med 2003;20:607-621. (Pubitemid 36966554)
5. Danser AH, Derkx FH, Admiraal PJ, et al. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994;35:1008-1018.
6. Okada Y, Yamanaka I, Sakamoto T, et al. Increased expression of angiotensin-converting enzyme in retinas of diabetic rats. Jpn J Ophthalmol 2001;45:585-591. (Pubitemid 34081771)
7. Otani A, Takagi H, Oh H, et al. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci 2000;41: 1192-1199. (Pubitemid 30187560)
8. Funatsu H, Yamashita H, Nakanishi Y, et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2002;86:311-315. (Pubitemid 34206346)
9. Early Treatment Diabetic Retinopathy Study Research Group, ETDRS Report Number 10.Ophthalmology 1991;98:786-806.
10. Holmguist B, Bünning P, Riodan JF. A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem 1979;95:540-548. (Pubitemid 9194370)
11. Chaturvedi N, Fuller JH, Pokras F, et al. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: The influence of ACE inhibition. Diabet Med 2001;18:288-294. (Pubitemid 32579358)
12. O'Driscoll G, Green D, Rankin J, et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997;100:678-684. (Pubitemid 27340517)
13. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Eng J Med 1993;329):1456-1462. (Pubitemid 23335891)
14. Zhang JZ, Xi X, Gao L, et al. Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy. Curr Eye Res 2007;32:883-889. (Pubitemid 350034786)
15. The EUCLID Study Group, Chaturvedi N. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349: 1787-1794. (Pubitemid 27257554)
16. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Eng J Med 2009;361:40-51.
17. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomized, placebo-controlled trials. Lancet 2008;372: 1394-1402.
18. Sjølie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomized placebo-controlled trial. Lancet 2008;372:1385-1393.
19. Danser AHJ, Van den Dorpel MA, Deinum J, et al. Renin, prorenin and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68:160-167. (Pubitemid 19028740)
20. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Eng J Med 1994;331:1480-1487.
21. Ishizaki E, Takai S, Ueki M, et al. Correlation between angiotensin- converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol 2006;141: 129-134. (Pubitemid 43016182)
22. Gilbert RE, Kelly DJ, Cox AJ, et al. Angiotensin converting enzyme inhibition ameliorates retinal over expression of vascular endothelial growth factor and hyper permeability in experimental diabetes. Diabetologia 2000;43:1360-1367.
23. Moravski CJ, Kelly DJ, Cooper ME, et al. Retinal neovascularization is prevented by blockade of the reninangiotensin system. Hypertension 2000;36:1099-1104.
24. Feman SS, Mericle RA, Reed GW, et al. Serum angiotensin converting enzyme in diabetic patients. Am J Med Sci 1993;305:280-284. (Pubitemid 23145438)
25. Hogeboom van Buggenum IM, Polak BC, Reichert- Thoen JW, et al. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 2002;45:203-209. (Pubitemid 34208382)
26. Otani A. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998;82: 619-628. (Pubitemid 28129033)
27. Maruichi M, Oku H, Takai S, et al. Measurement of activities in two different angiotensin II generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of vitreoretinal diseases: A possible involvement of chymase in the pathogenesis of macular hole patients. Curr Eye Res 2004;29:321-325. (Pubitemid 40095017)
28. Tikellis C, Jonhston CI, Forbes JM, et al. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res 2004;29:419-427. (Pubitemid 40138381)
29. Kramkowski K, Mogielnicki A, Buczko W. The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol 2006;57:529-539. (Pubitemid 46096103)
30. Vaajanen A, Luhtala S, Oksala O, et al. Does the renin- angiotensin system also regulate intra-ocular pressure? Ann Med 2008;40:418-427.
31. Luhtaha S, Vaajanen A, Oksala O, et al. Activities of angiotensin- converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. J Ocul Pharmacol Ther 2009;25:23-28.